Compare EVTL & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVTL | IMUX |
|---|---|---|
| Founded | 2016 | 2016 |
| Country | United Kingdom | United States |
| Employees | 454 | 66 |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 338.7M | 152.6M |
| IPO Year | N/A | 2013 |
| Metric | EVTL | IMUX |
|---|---|---|
| Price | $2.69 | $12.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 6 |
| Target Price | $12.70 | ★ $36.00 |
| AVG Volume (30 Days) | ★ 3.9M | 1.6M |
| Earning Date | 03-24-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.90 | $0.51 |
| 52 Week High | $7.60 | $13.30 |
| Indicator | EVTL | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 51.77 | 82.91 |
| Support Level | $2.20 | $0.75 |
| Resistance Level | $3.55 | N/A |
| Average True Range (ATR) | 0.20 | 1.09 |
| MACD | 0.05 | 0.26 |
| Stochastic Oscillator | 79.23 | 85.77 |
Vertical Aerospace Ltd is engaged in making air travel personal, on-demand, and carbon-free. The company is a world-wide aerospace and technology company that is pioneering electric aviation, focused on designing, manufacturing, and selling a zero-emission eVTOL aircraft for use in the AAM market, using the technology from the aerospace, automotive, and energy industries. The VX4, Vertical's flagship aircraft, is a piloted electric vertical take-off and landing (eVTOL) vehicle capable of carrying four passengers. The Group operates as a single operating segment and one reporting segment, being the development and commercialization of eVTOL technology.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.